MX2 Antibody

What is MX2 protein and why is it important in research?

MX2 (Myxovirus resistance 2, also known as MXB) is a dynamin-like GTPase belonging to the Dynamin/Fzo/YdjA protein family. In humans, the canonical MX2 protein consists of 715 amino acid residues with a molecular mass of approximately 82.1 kDa . MX2 is an interferon-stimulated gene (ISG) with significant importance in antiviral immunity research, particularly for its role as a potent inhibitor of HIV-1 infection . It functions as a late post-entry suppressor of HIV-1 by blocking the nuclear accumulation of viral cDNAs, making it a critical component of interferon-mediated antiviral defense mechanisms . Understanding MX2 is essential for researchers studying host restriction factors, innate immunity, and potential therapeutic targets for viral infections.

How does MX2 differ from MX1/MXA in structure and function?

While MX1 and MX2 are closely related and share similar domain architectures, several key differences exist:

The extended N-terminus of MX2 distinguishes it from MX1 and is essential for its anti-HIV-1 activity—transferring just the N-terminal 91 amino acids of MX2 to MX1 can confer anti-HIV-1 activity to the chimeric protein .

What are the primary applications of MX2 antibodies in research?

MX2 antibodies serve multiple experimental purposes in research:

• Protein Detection: Western blotting to quantify expression levels, particularly in interferon-stimulated cells

• Localization Studies: Immunofluorescence (IF) and immunocytochemistry (ICC) to visualize MX2 at the nuclear envelope

• Interaction Analysis: Immunoprecipitation to identify binding partners such as components of the nuclear pore complex

• Tissue Expression Patterns: Immunohistochemistry (IHC) to map expression in different tissues

• ELISA: Quantitative analysis of MX2 levels in biological samples

When selecting an MX2 antibody, researchers should consider their specific application, as different antibodies may perform optimally in different assays. For example, the search results indicate 152 MX2 antibodies from 23 suppliers with varying applications and reactivities .

How can researchers validate the specificity of MX2 antibodies?

To ensure experimental integrity, thorough validation of MX2 antibodies is essential:

• CRISPR/Cas9 knockout controls: Generate MX2-null cells to confirm antibody specificity

• siRNA knockdown: Compare antibody signal in cells treated with MX2-specific siRNA versus control siRNA

• Overexpression system: Test antibody recognition of tagged recombinant MX2 (ensuring the tag doesn't interfere with epitope recognition)

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

• Multi-antibody validation: Use antibodies targeting different epitopes of MX2 to confirm consistent results

• Isoform specificity testing: Determine if the antibody distinguishes between the 78-kDa and 76-kDa isoforms

Researchers should also verify whether the antibody cross-reacts with MX1, given their structural similarities, by performing parallel experiments with MX1 knockout or overexpression systems.

How can researchers effectively study MX2 oligomerization using antibody-based techniques?

MX2 oligomerization appears critical for its antiviral function, with research indicating that monomeric MX2 lacks antiviral activity while lower-order oligomerization (unlike MX1) may be sufficient for HIV-1 inhibition . To study this:

• Chemical cross-linking followed by immunoblotting:

  • Treat cells with membrane-permeable cross-linkers (e.g., DSS, BS3)

  • Lyse cells and perform Western blotting with MX2 antibodies

  • Analyze band patterns corresponding to monomers, dimers, and higher-order oligomers

• Co-immunoprecipitation of differentially tagged MX2:

  • Co-express FLAG-tagged and HA-tagged MX2 variants

  • Immunoprecipitate with anti-FLAG antibodies

  • Detect co-precipitated HA-tagged MX2 by immunoblotting

• Native PAGE analysis:

  • Prepare samples under non-denaturing conditions

  • Perform electrophoresis followed by immunoblotting with MX2 antibodies

  • Compare wild-type protein with oligomerization-defective mutants (e.g., mutations at stalk interfaces)

• Proximity ligation assays (PLA):

  • Use two different MX2 antibodies recognizing distinct epitopes

  • Visualize oligomerization as fluorescent spots through PLA

Researchers should include key controls such as the MX2 stalk mutants (V578A, F647A) and the L2 loop mutation (YRGK487-AAAA490) which have been shown to disrupt different oligomerization interfaces .

What methods are effective for studying MX2 phosphorylation and its functional impact?

Recent findings show that serine phosphorylation at positions 14, 17, and 18 of the MX2 N-terminal domain suppresses its antiviral function . To study this regulatory mechanism:

• Phospho-specific antibodies:

  • Use or develop antibodies that specifically recognize phosphorylated serines at positions 14, 17, and 18

  • Compare phosphorylation levels under different conditions (e.g., viral infection, interferon stimulation)

• Phosphatase treatment:

  • Treat immunoprecipitated MX2 with lambda phosphatase

  • Compare mobility shifts and activity before and after treatment

• Mass spectrometry analysis:

  • Immunoprecipitate MX2 under various conditions

  • Perform phospho-peptide enrichment followed by LC-MS/MS

  • Quantify phosphorylation at specific residues

• Functional studies with phosphomimetic and phosphodeficient mutants:

  • Generate S14/17/18D (phosphomimetic) and S14/17/18A (phosphodeficient) mutants

  • Compare their subcellular localization, HIV-1 capsid binding, and antiviral activity

• MLCP inhibition studies:

  • Use specific inhibitors of myosin light chain phosphatase (MLCP) subunits MYPT1 and PPP1CB

  • Monitor effects on MX2 phosphorylation and antiviral activity

This approach provides insights into how phosphorylation regulates MX2 function and potentially reveals therapeutic opportunities to enhance innate immunity against HIV-1 .

How can researchers investigate MX2 interactions with nuclear pore components?

MX2 interacts with multiple components of the nuclear pore complex (NPC), which is crucial for its localization and antiviral function . To study these interactions:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate MX2 using specific antibodies

  • Detect associated nucleoporins (e.g., NUP214) by Western blotting

  • Include RRR11-13A mutant as a negative control

• Proximity-based labeling:

  • Generate MX2 fusions with BioID or APEX2

  • Identify proximal proteins through streptavidin pulldown and mass spectrometry

  • Validate hits with co-IP or fluorescence microscopy

• FRET/BRET assays:

  • Create fluorescent protein fusions of MX2 and nucleoporins

  • Measure energy transfer as an indication of protein-protein interaction

  • Compare wild-type and mutant proteins

• Yeast two-hybrid screening:

  • Use the N-terminal domain of MX2 as bait

  • Screen for interactions with nucleoporins and transport factors

  • Validate positive hits in mammalian cells

• siRNA-mediated depletion:

  • Silence expression of specific nuclear pore components (e.g., NUP214, TNPO1)

  • Assess effects on MX2 localization and antiviral activity

  • Use confocal microscopy to visualize changes in nuclear envelope association

Research has shown that transportin-1 (TNPO1) and the phenylalanine-glycine (FG) repeat-containing nucleoporin NUP214 are particularly important for MX2 function, and their simultaneous depletion reduces MX2 accumulation at the nuclear envelope .

What techniques can researchers use to distinguish between the two MX2 isoforms?

MX2 exists as two isoforms: a longer 78-kDa antiviral form and a shorter 76-kDa non-antiviral form resulting from an alternative translation initiation site at methionine 26 . To distinguish these isoforms:

• Isoform-specific antibodies:

  • Use antibodies targeting the first 25 amino acids (present only in the 78-kDa isoform)

  • Confirm specificity using recombinant proteins of both isoforms

• SDS-PAGE resolution:

  • Optimize gel conditions (e.g., 6% polyacrylamide, extended run time) to separate the closely sized isoforms

  • Use precision plus molecular weight markers for accurate sizing

• N-terminal mutants:

  • Generate an M26A mutant to prevent formation of the shorter isoform

  • Compare with wild-type MX2 expression pattern

• Subcellular fractionation:

  • Separate nuclear envelope and cytoplasmic fractions

  • The 78-kDa isoform should be enriched in nuclear envelope fractions

  • The 76-kDa isoform should be predominantly cytoplasmic

• Immunofluorescence microscopy:

  • Use antibodies that recognize both isoforms

  • The 78-kDa isoform shows nuclear envelope staining

  • The 76-kDa isoform shows diffuse cytoplasmic staining

Understanding the ratio and regulation of these isoforms is crucial when interpreting experimental results, as their antiviral properties differ significantly.

How should researchers design control experiments when studying MX2 antiviral activity?

• Positive controls:

  • Wild-type MX2 in interferon-treated cells

  • MX1(N-MX2) chimera containing the N-terminal domain of MX2

• Negative controls:

  • Empty vector

  • MX1 (lacks anti-HIV-1 activity)

  • MX2 RRR11-13A mutant (disrupts antiviral function)

  • MX2 GTPase-deficient mutants

• Isoform controls:

  • M1A mutant (expressing only the 76-kDa isoform)

  • M26A mutant (expressing only the 78-kDa isoform)

• Phosphorylation controls:

  • Phosphomimetic mutants (S14/17/18D)

  • Phosphodeficient mutants (S14/17/18A)

• Localization controls:

  • Nuclear localization signal (NLS) mutants

  • Forced nuclear envelope localization constructs

• Virus controls:

  • HIV-1 with capsid mutations known to escape MX2 restriction

  • Non-restricted control viruses (e.g., murine leukemia virus)

These controls help distinguish MX2-specific effects from non-specific effects and provide deeper insights into the mechanisms of restriction.

What are the key considerations for studying MX2-HIV-1 capsid interactions?

The interaction between MX2 and HIV-1 capsid is central to MX2's antiviral activity . To effectively study this interaction:

• In vitro binding assays:

  • Purify recombinant MX2 (full-length or N-terminal domain)

  • Generate HIV-1 capsid assemblies or monomers

  • Perform pull-down assays followed by Western blotting

  • Include RRR11-13A mutant as negative control

• Cellular co-localization studies:

  • Express fluorescently tagged MX2 and capsid proteins

  • Perform high-resolution microscopy (e.g., confocal, STORM)

  • Quantify co-localization coefficients

• Crosslinking-mass spectrometry:

  • Use chemical or photo-crosslinkers to stabilize transient interactions

  • Identify interaction interfaces by mass spectrometry

  • Validate findings through mutagenesis

• Capsid binding competition assays:

  • Test if known capsid-binding factors (CPSF6, TNPO3) compete with MX2

  • Assess if phosphorylation status affects competition

• Structural studies:

  • Use cryo-EM to visualize MX2 bound to assembled capsid

  • Combine with computational modeling to predict interaction interfaces

• Capsid mutant panel testing:

  • Screen MX2 sensitivity against a panel of HIV-1 capsid mutants

  • Map residues critical for the interaction

Remember that the N-terminal domain, particularly the triple-arginine motif at positions 11-13, is crucial for capsid binding and antiviral activity .